Navigation Links
Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Date:11/12/2007

MONTVALE, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX: SYI) announced today, dosing of the first patient in BENEFICIAL, a 100-patient Phase 2 clinical trial of alagebrium (ALT-711), a novel compound designed to act as an Advanced Glycation End-product (AGE)-cross-link breaker, in patients with chronic heart failure (CHF). The BENEFICIAL study (Double- blind, placebo-controlled, randomized trial evaluating the efficacy and safety of alagebrium) is designed to measure the effect of alagebrium on exercise tolerance in patients with CHF. The Company plans to use the experience and results of this study to guide development of its Phase 3 program for alagebrium in CHF. The single-site Phase 2 trial is being conducted at the University Medical Centre Groningen, The Netherlands and the principal investigator is Adriaan A. Voors, M.D., Associate Professor of Cardiology.

The objective of the BENEFICIAL study is to improve maximal oxygen consumption (VO2max), which is highly correlated with an improvement in myocardial function in patients with CHF. Diastolic and systolic function will be measured by tissue velocity imaging with echocardiography. The ability of alagebrium to break down AGEs will also be measured by tracking levels of carboxy-methyllysine (an AGE) in the skin using an auto-fluorescence device.

"Alagebrium is the first orally active AGE-cross-link breaker that has been evaluated in preclinical and clinical studies, and studies using animal models of diabetes and aging have demonstrated its effect in reversing cardiac stiffening," said Dr. Voors. "We are encouraged by the potential that alagebrium has demonstrated in our preclinical models, and are aggressively pursuing cli
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 2015 Future Market Insights (FMI) ... Glucose Monitoring Systems Market: Global Industry Analysis and Opportunity ... global continuous glucose monitoring systems market was valued at ... reach US$ 788.4 Mn by 2020, registering a CAGR ... Global continuous glucose monitoring systems market is ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... of Defense Continues Study of Copper as Effective ... Improving Indoor Air Quality, NEW YORK, Nov. ... determining the,antimicrobial effectiveness of copper, brass and bronze ... CDA President Andrew G.,Kireta Sr. Of the ...
... To Enroll 4,000 Patients Worldwide, MENLO PARK, ... it is launching a global Phase III clinical ... novel combination therapy CGT-2168.,The program, which includes the ... at hundreds of sites in the United States, ...
Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy 2
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... Those looking to catch a new and refreshing show on Broadway, look no ... and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic Town has proven itself ... various plastic surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and ... Botox and fillers. , Staying up to date with the latest cosmetic ...
(Date:7/31/2015)... ... 2015 , ... “Engage: Don’t Just Age” will be the ... symposiums, hosted by Massachusetts-based Harmony Healthcare International at Foxwoods Resort Casino in ... executives, administrators, directors of nursing, rehabilitation managers and other management and corporate personnel ...
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), ... we treat aging diseases. , BioViva announces it has begun a fundraiser through ... Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of the money ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3
... Feb. 3 When Americans are asked about the ... Poll, commissioned by the,National Court Appointed Special Advocate (CASA) ... nothing about the experiences of children in,foster care, and ... these,children. When adults do think of children in ...
... and PACS Industry Veteran , Shawn Gibbons ... Compressus, Inc., leaders in healthcare IT systems interoperability ... of Janine Broda to chief marketing officer and ... president and general manager of the MEDxConnect(TM) division.Proven ...
... -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ... and distributor of high-quality,pharmaceutical grade glucose products ... invited to make a corporate presentation at ... Conference. , This ...
... are found to slow damage , , TUESDAY, Feb. 3 ... loss caused by Alzheimer,s disease, a new study says. ... University found that insulin acts as a shield that deflects ... responsible for forming memories. , "Therapeutics designed to ...
... Mich., Feb. 3 Perrigo Company,(Nasdaq: PRGO ; TASE) today announced results for its fiscal year 2009 second,quarter and six months that ended December 27, 2008. ... Perrigo Company, (in ... Second Quarter Six Months, ... 2009 2008 2009 ...
... MOUNTAIN VIEW, Calif., Feb. 3 MAP Pharmaceuticals, ... that the waiting period under the Hart-Scott-Rodino Act ... with AstraZeneca has expired, and the agreement is ... AstraZeneca will jointly develop and commercialize UDB, MAP ...
Cached Medicine News:Health News:National CASA Association Aims to Eliminate the Foster Care Stigma 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 2Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 3Health News:Insulin May Protect Against Alzheimer's 2Health News:Perrigo Reports Record Second Quarter Sales 2Health News:Perrigo Reports Record Second Quarter Sales 3Health News:Perrigo Reports Record Second Quarter Sales 4Health News:Perrigo Reports Record Second Quarter Sales 5Health News:Perrigo Reports Record Second Quarter Sales 6Health News:Perrigo Reports Record Second Quarter Sales 7Health News:Perrigo Reports Record Second Quarter Sales 8Health News:Perrigo Reports Record Second Quarter Sales 9Health News:Perrigo Reports Record Second Quarter Sales 10Health News:Perrigo Reports Record Second Quarter Sales 11Health News:Perrigo Reports Record Second Quarter Sales 12Health News:Perrigo Reports Record Second Quarter Sales 13Health News:Perrigo Reports Record Second Quarter Sales 14Health News:Perrigo Reports Record Second Quarter Sales 15Health News:Perrigo Reports Record Second Quarter Sales 16Health News:Perrigo Reports Record Second Quarter Sales 17Health News:Perrigo Reports Record Second Quarter Sales 18Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 2Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 3Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 4
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
Intermittent catheter - SpeediCath™ is pre-hydrated and ready to use right out of the package. Just open, cath and get on with your life....
The Medtronic® Resting Heart™ System offers a new approach to reducing cardiac surgery morbidity....
This adapter features a female luer on the single leg. A rigid "Y" has two legs with white clamps and terminate with male luers....
Medicine Products: